Real-time earthquake hazard assessment in California; the early post-earthquake damage assessment tool and the Caltech-USGS broadcast of earthquakes

A real-time earthquake monitoring system which provides source parameters to user groups through a commercial paging service is now in place in California. A GIS-based system to predict and display near real-time damage and casualty estimates is currently being developed by EQE International under contract with the State of California. These new technologies offer immediate tangible benefits to state and local governments, utilities, lifelines and corporations with facilities or operations at risk. This paper will outline the development of these new technologies, identify the contributions they will make to emergency management and explore some directions these innovative systems may take in the future

NDM-506: CURRENT METHODS AND FUTURE ADVANCES FOR RAPID, REMOTE-SENSING-BASED WIND DAMAGE ASSESSMENT

Remote-sensing information provides an effective basis for the rapid assessment of wind damage. The development of remote-sensing based assessments has received notable attention over the past decade, although automated algorithms have not yet achieved the speed, objectivity, and reliability desired for practical implementation in time-critical damage assessments. The current standard practice for making swift, objective, and widespread assessments of wind damage currently consists of rapid visual interpretation of first-available imagery. Techniques for rapidly accomplishing widespread damage assessments by visual inspection have been implemented in recent major tornado outbreaks in Birmingham-Tuscaloosa, Alabama and Joplin, Missouri (2011). Quickly emerging technologies, such as unmanned aerial vehicles (UAVs) and laser scanners, are helping to improve both the speed and the accuracy of damage assessments, in particular for rapid and target-specific data collection at very high spatial resolutions. Applications of these emerging technologies following recent severe tornadoes at Pilger, Nebraska (2014) and Pampa, Texas (2015) have demonstrated their role in helping to refine strategies for making rapid semi-automated damage assessments. Algorithms for comparing before-and-after remote sensing imagery are also of great interest for the future development of automated damage detection. Current development activities are centered on high-resolution before-and-after aerial images of recent tornado damage

Benefit-Cost Analysis of FEMA Hazard Mitigation Grants

Mitigation ameliorates the impact of natural hazards on communities by reducing loss of life and injury, property and environmental damage, and social and economic disruption. The potential to reduce these losses brings many benefits, but every mitigation activity has a cost that must be considered in our world of limited resources. In principle benefit-cost analysis (BCA) can be used to assess a mitigation activity’s expected net benefits (discounted future benefits less discounted costs), but in practice this often proves difficult. This paper reports on a study that refined BCA methodologies and applied them to a national statistical sample of FEMA mitigation activities over a ten-year period for earthquake, flood, and wind hazards. The results indicate that the overall benefit-cost ratio for FEMA mitigation grants is about 4 to 1, though the ratio varies according to hazard and mitigation type.

Real-Time Loss Estimation as an Emergency Response Decision Support System: The Early Post-Earthquake Damage Assessment Tool (EPEDAT)

At the time of the Northridge earthquake, a number of new technologies, including real-time availability of earthquake source data, improved loss estimation techniques, Geographic Information Systems and various satellite-based monitoring systems, were either available or under consideration as emergency management resources. The potential benefits from these technologies for earthquake hazard mitigation, response and recovery, however, were largely conceptual. One of the major lessons learned from the January 17, 1994 earthquake was that these technologies could confer significant advantages in understanding and managing a major disaster, and that their integration would contribute a significant additional increment of utility. In the two and half years since the Northridge earthquake, important strides have been taken toward the integration of relatively discrete technologies in a system which provides real-time estimates of regional damage, losses and population impacts. This paper will describe the development, operation and application of the first real-time loss estimation system to be utilized by an emergency services organization

Direct Economic Losses in the Northridge Earthquake: A Three-Year Post-Event Perspective

The Northridge earthquake will long be remembered for the unprecedented losses incurred as a result of a moderate-size event in a suburban area of Los Angeles. Current documented costs indicate that this event is the costliest disaster in U.S. history. Although it is difficult to estimate the full cost of this event, it is quite possible that total losses, excluding indirect effects, could reach as much as $40 billion. This would make the Northridge earthquake less severe than the Kobe event, which occurred exactly one year after the Northridge earthquake, but adds a bit of realism that a Kobe-type disaster is possible in the U.S. This paper attempts to put into perspective the direct capital losses associated with the Northridge earthquake. In doing so, we introduce the concept of hidden and/or undocumented costs that could double current estimates. In addition, we present the notion that a final estimate of loss may be impossible to achieve, although costs do begin to level off two years after the earthquake. Finally, we attempt to reconcile apparent differences between loss totals for two databases tracking similar information

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas

Background: The prognosis for malignant gliomas remains dismal. We addressed the safety, feasibility and preliminary clinical activity of the vaccinations using autologous glioma cells and interleukin (IL)-4 gene transfected fibroblasts. Methods: In University of Pittsburgh Cancer Institute (UPCI) protocol 95-033, adult participants with recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) received gross total resection (GTR) of the recurrent tumors, followed by two vaccinations with autologous fibroblasts retrovirally transfected with TFG-IL4-Neo-TK vector admixed with irradiated autologous glioma cells. In UPCI 99-111, adult participants with newly diagnosed GBM or AA, following GTR and radiation therapy, received two intradermal vaccinations with the TFG-IL4-Neo-TK-transfected fibroblasts admixed with type-1 dendritic cells (DC) loaded with autologous tumor lysate. The participants were evaluated for occurrence of adverse events, immune response, and clinical response by radiological imaging. Results and Discussion: In UPCI 95-033, only 2 of 6 participants received the vaccinations. Four other participants were withdrawn from the trial because of tumor progression prior to production of the cellular vaccine. However, both participants who received two vaccinations demonstrated encouraging immunological and clinical responses. Biopsies from the local vaccine sites from one participant displayed IL-4 dose-dependent infiltration of CD4+ as well as CD8+ T cells. Interferon (IFN)-γ Enzyme-Linked Immuno-SPOT (ELISPOT) assay in another human leukocyte antigen (HLA)-A2+ participant demonstrated systemic T-cell responses against an HLA-A2-restricted glioma-associated antigen (GAA) epitope EphA2883-891. Moreover, both participants demonstrated clinical and radiological improvement with no evidence of allergic encephalitis, although both participants eventually succumbed with the tumor recurrence. In 99-111, 5 of 6 enrolled participants received scheduled vaccinations with no incidence of major adverse events. Monocyte-derived DCs produced high levels of IL-12 p70. Treatment was well tolerated; however, we were unable to observe detectable IFN-γ post-vaccine responses or prolonged progression-free survival in these participants. Conclusion: Feasibility challenges inherent in the generation of a patient-specific gene transfection-based vaccine strongly suggests the need for more practical formulations that would allow for the timely administration of vaccines. Nevertheless, successful generation of type-1 DCs and preliminary safety in the current study provide a strong rationale for further efforts to develop novel glioma vaccines. © 2007 Okada et al; licensee BioMed Central Ltd